Publikationen
Hier stellen wir Ihnen aktuelle, ausgewählte Veröffentlichungen von Autor:Innen aus dem ifi-Institut für interdisziplinäre Medizin vor:
265. Buggisch P, Petersen J
Therapiestrategien bei Hepatitis B, C und D - Update zu Diagnostik, Behandlung und Prävention
MMW - Fortschritte der Medizin 2025.09- Springer Medizin Verlag GmbH
264. Lange S, Baehr C, Cakman-Hinrichs NI, et al. ReLink strategy in diagnosed-but-untreated hepatitis C-positive patients in Germany: report from a single center. Die ReLink-Strategie bei diagnostizierten aber unbehandelten Hepatitis C-positiven Patient*innen in Deutschland: Bericht aus einem einzelnen Zentrum - Hepatitis C ReLink-Projekt Deutschland. Z Gastroenterol. 2024;62(10):1701-1707. doi:10.1055/a-2349-2767 Hamburg 2024
263. Hirschfield GM, Bowlus CL, Marlyn JM, Kremer AE, Vierling JM, ,Kowdley KV, Levy C, Villamil A, Ladrón de Guevara Cetina AL,
Janczewska E,Zigmond E,Jeong SH, Yilmaz Y, Kallis Y, Corpechot C, Buggisch P, Invernizzi P, Londoño Hurtado ML, Bergheanu S, Yang K, Choi Y-J, Crittenden DB, McWherter C. A, Ph.D. for the RESPONSE Study Group*
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
The New England Journal of Medicine 2024 Feb. DOI: 10.1056/NEJMoa2312100. Neijm 2024
262. Cornberg M, Sandmann S, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J
S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVC) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11)
Z Gastroenterol. 2021 Jul;59(7):691-776. doi: 10.1055/a-1498-2512. Epub 2021 Jul 12.
261. Dandri M, Petersen J
cccDNA Maintenance in Chronic Hepatitis B - Targeting the Matrix of Viral Replication
Infect Drug Resist. 2020 Oct 29; 13:3873-3886. doi: 10.2147/IDR.S240472. eCollection 2020.
260. Lampertico P, Berg T, Buti M, Pathil A, Petersen J, Ryder S D, Zoulim F, Botros I, Flaherty J F, Jump B, Op den Brouw M L, van Troostenburg A, Ramroth H, ReCoRd (Retrospective, Cohort, Renal, Viread) Investigators' Group
Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study
Aliment Pharmacol Ther. 2020 Aug;52(3):500-512. doi: 10.1111/apt.15901. Epub 2020 Jun 25.
259. Yuen M-F, Schiefke I, Yoon J-H, Ahn S H, Heo J, Kim J H, Chan H L Y, Yoon K T, Klinker H, Manns M, Petersen J, Schluep T, Hamilton J, Given B D, Ferrari C, Lai C-L, Locarnini S A, Gish R G
RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection
Hepatology. 2020 Jul;72(1):19-31. doi: 10.1002/hep.31008. Epub 2020 Apr 23.
258. Gabriel MM, Kircheis G, Hardtke S, Markwardt D, Buggisch P, Mix H, Grüngreiff K, Welzel TM, Kälsch J, Hartmann H, Gerbes AL, Karpowitz MV, Seeliger B, Wedemeyer H, Weissenborn K; HepNet HE-Register Study Group
Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry study
Eur J Gastroenterol Hepatol. 2020 Jul 8. doi: 10.1097/MEG.0000000000001822. Online ahead of print.
257. Dietz J, Vermehren J, Matschenz K, Buggisch P, Klinker H, Schulze Zur Wiesch J, Hinrichsen H, Peiffer KH, Graf C, Discher T, Trauth J, Schattenberg JM, Piecha F, Mauss S, Niederau C, Müller T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C; European HCV Resistance Study Group
Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions
Liver Int. 2020 Jul 8. doi: 10.1111/liv.14591. Online ahead of print.
256. Dietz J, Kalinina OV, Vermehren J, Peiffer KH, Matschenz K, Buggisch P, Niederau C, Schattenberg JM, Müllhaupt B, Yerly S, Ringelhan M, Schmid RM, Antoni C, Müller T, Schulze Zur Wiesch J, Piecha F, Moradpour D, Deterding K, Wedemeyer H, Moreno C, Berg T, Berg CP, Zeuzem S, Welsch C, Sarrazin C; European HCV Resistance Study Group
Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection
J Viral Hepat. 2020 May 12. doi: 10.1111/jvh.13322. Online ahead of print.
255. Schmitt A, Günther R, Mauss S, Boeker KHW, Buggisch P, Hillenbrand H, John C, Klinker H, Pathil A, Simon KG, Serfert Y, Niederau C, Vermehren J, Wedemeyer H, Sarrazin C
Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy - data from the German hepatitis C registry (DHC-R)
Z Gastroenterol. 2020 Apr;58(4):341-351. doi: 10.1055/a-1068-3056. Epub 2020 Feb 10.
254. Becker-Assmann J, Fard-Aghaie MH, Kantas A, Makridis G, Reese T, Wagner KC, Petersen J, Buggisch P, Stang A, von Hahn T, Oldhafer KJ
Diagnostic and prognostic significance of α-fetoprotein in hepatocellular carcinoma
Chirurg. 2020 Sep;91(9):769-777. doi: 10.1007/s00104-020-01118-6.
253. Labenz C, Adarkwah CC, Wörns MA, Miehlke S, Hofmann WP, Buggisch P, Galle PR, Frieling T, Labenz J
Management of hepatic encephalopathy in Germany: a survey among physicians
Z Gastroenterol. 2020 Jan;58(1):49-56. doi: 10.1055/a-1010-6974. Epub 2020 Jan 13.
252. Tacke F, Boeker KHW, Klinker H, Heyne R, Buggisch P, Pathil A, Wiegand J, Cornberg M, Lange C, Berg T, Zeuzem S, Mauss S
Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs
Liver Int. 2020 Mar;40(3):539-548. doi: 10.1111/liv.14186. Epub 2019 Jul 25.
251. Graf C, Mondorf A, Knop V, Peiffer KH, Dietz J, Friess J, Wedemeyer H, Buggisch P, Mauss S, Berg T, Rausch M, Sprinzl M, Klinker H, Hinrichsen H, Bronowicki JP, Haag S, Hüppe D, Lutz T, Poynard T, Zeuzem S, Friedrich-Rust M, Sarrazin C, Vermehren J
Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection
J Clin Med. 2019 Dec 2;8(12):2101. doi: 10.3390/jcm8122101.
250. Dietz J, Spengler U, Müllhaupt B, Schulze Zur Wiesch J, Piecha F, Mauss S, Seegers B, Hinrichsen H, Antoni C, Wietzke-Braun P, Peiffer KH, Berger A, Matschenz K, Buggisch P, Backhus J, Zizer E, Boettler T, Neumann-Haefelin C, Semela D, Stauber R, Berg T, Berg C, Zeuzem S, Vermehren J, Sarrazin C; European HCV Resistance Study Group
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections
Clin Gastroenterol Hepatol. 2019 Nov 6:S1542-3565(19)31260-1. doi: 10.1016/j.cgh.2019.10.051.
249. Wiegand J, Buggisch P, Mauss S, Boeker KHW, Klinker H, Müller T, Günther R, Serfert Y, Manns MP, Zeuzem S, Berg T, Hinrichsen H, C-Registry GH
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register)
Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1424-1431. doi: 10.1097/MEG.0000000000001426.
248. Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, Manns M, Kaita K, Krastev Z, Lee SS, Cathcart AL, Crans G, Op den Brouw M, Jump B, Gaggar A, Flaherty J, Buti M
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection
Liver Int. 2019 Oct;39(10):1868-1875. doi: 10.1111/liv.14155. Epub 2019 Jul 10
247. Sarrazin C, Buggisch P, Mauss S, Müller T, Zimmermann T, Klinker H, Pathil-Warth A, Schlag M, Nalpas C, Wegner S, Lonjon-Domanec I, Simon KG
Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015
Z Gastroenterol. 2019 May;57(5):584-592. doi: 10.1055/a-0859-7561. Epub 2019 May 13.
246. Buggisch P, Wursthorn K, Stoehr A, Atanasov PK, Supiot R, Lee J, Ting J, Petersen J
Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany
PLoS One. 2019 Apr 4;14(4):e0214795. doi: 10.1371/journal.pone.0214795. eCollection 2019.
245. Christensen S, Buggisch P, Mauss S, Böker KH, Müller T, Klinker H, Zimmermann T, Serfert Y, Weber B, Reimer J, Wedemeyer H; German Hepatitis C-Registry
Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy-Data From the German Hepatitis C-Registry (DHC-R)
Subst Abuse. 2019 Mar 28;13:1178221819835847. doi: 10.1177/1178221819835847. eCollection 2019.
244. Ferenci P, Bourgeois S, Buggisch P, Norris S, Curescu M, Larrey D, Marra F, Kleine H, Dorr P, Charafeddine M, Crown E, Bondin M, Back D, Flisiak R
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries
J Viral Hepat. 2019 Jun;26(6):685-696. doi: 10.1111/jvh.13080. Epub 2019 Mar 5.
243. Zeuzem S, Bourgeois S, Greenbloom S, Buti M, Aghemo A, Lampertico P, Janczewska E, Lim SG, Moreno C, Buggisch P, Tam E, Corbett C, Willems W, Vijgen L, Fevery B, Ouwerkerk-Mahadevan S, Ackaert O, Beumont M, Kalmeijer R, Sinha R, Biermer M; OMEGA-1 study team
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-infected Patients without Cirrhosis: OMEGA-1
Hepatology. 2019 Jun;69(6):2349-2363. doi: 10.1002/hep.30527. Epub 2019 Mar 14.
242. Hüppe D, Serfert Y, Buggisch P, Mauss S, Böker KHW, Müller T, Klinker H, Günther R, Berg T, Cornberg M, Niederau C, Sarrazin C, Simon KG, Zeuzem S, Manns MP, Wedemeyer H
4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)
Z Gastroenterol. 2019 Jan;57(1):27-36. doi: 10.1055/a-0821-7188. Epub 2019 Jan 14
241. Knop V, Hofmann WP, Buggisch P, Klinker H, Mauss S, Günther R, Hinrichsen H, Hüppe D, Pfeiffer-Vornkahl H, Simon KG, Berg T, Manns MP, Friedrich-Rust M; German Hepatitis C-Registry
Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment
J Viral Hepat. 2019 Feb;26(2):224-230. doi: 10.1111/jvh.13021. Epub 2018 Nov 8
240. Maasoumy B, Buggisch P, Mauss S, Boeker KHW, Müller T, Günther R, Zimmermann T, Manns MP, Sarrazin C, Hüppe D, Wedemeyer H, Vermehren J
Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients
Liver Int. 2018 Nov;38(11):1906-1910. doi: 10.1111/liv.13932. Epub 2018 Aug 10.
239. Buggisch P, Zeuzem S
Reply to: "Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?"
J Hepatol. 2018 Jun 6. pii: S0168-8278(18)32051-8. doi: 10.1016/j.jhep.2018.05.005. [Epub ahead of print]
238. Höner Zu Siederdissen C, Buggisch P, Böker K, Schott E, Klinker H, Pathil A, Pfeiffer-Vornkahl H, Berg T, Sarrazin C, Hüppe D, Manns MP, Mauss S
Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting
United European Gastroenterol J. 2018 Mar;6(2):213-224. doi: 10.1177/2050640617716607.
237. Christensen S, Buggisch P, Mauss S, Böker KHW, Schott E, Klinker H, Zimmermann T, Weber B, Reimer J, Serfert Y, Wedemeyer H
Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
Addiction. 2018 May;113(5):868-882
236. Zoulim F, Moreno C, Lee SS, Buggisch P, Horban A, Lawitz E, Corbett C, Lenz O, Fevery B, Verbinnen T, Shukla U, Jessner W
A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection
Virol J. 2018 Jan 30;15(1):26. doi: 10.1186/s12985-018-0936-4.
235. Buggisch P, Vermehren J, Mauss S, Günther R, Schott E, Pathil A, Boeker K, Zimmermann T, Teuber G, Vornkahl HP, Simon KG, Niederau C, Wedemeyer H, Zeuzem S
Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C
J Hepatol. 2017 Nov 11. pii: S0168-8278(17)32431-5. doi: 10.1016/j.jhep.2017.11.009.
234. Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C; European HCV Resistance Study Group
Patterns of Resistance-associated Substitutions in Patients With Chronic HCV Infection Following Treatment with Direct-acting Antivirals
Gastroenterology. 2018 Mar;154(4):976-988
233. Pedro Cahn, Richard Kaplan, Paul E Sax, Kathleen Squires, ONCEMRK Study Group (including A. Stoehr):
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
The Lancet HIV, Volume 4, Issue 11, November 2017, Pages e486-e494
232. Berg T, Petersen J; FINITE [First investigation in stopping TDF treatment after long-term virological suppression in HBeAg-negative chronic hepatitis B]; study authors.:
Predicting long-term response after stopping nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B.
J Hepatol. 2017 Oct 6. pii: S0168-8278(17)32345-0. doi: 10.1016/j.jhep.2017.09.025. [Epub ahead of print] No abstract available. PMID: 28993185.
231. Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, Gitlin N, Gordon SC, Odin JA, Sheridan D, Wörns MA, Clark V, Corless L, Hartmann H, Jonas ME, Kremer AE, Mells GF, Buggisch P, Freilich BL, Levy C, Vierling JM, Bernstein DE, Hartleb M, Janczewska E, Rochling F, Shah H, Shiffman ML, Smith JH, Choi YJ, Steinberg A, Varga M, Chera H, Martin R, McWherter CA, Hirschfield GM.:
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.
Lancet Gastroenterol Hepatol. 2017 Oct;2(10):716-726. doi: 10.1016/S2468-1253(17)30246-7. Epub 2017 Aug 14. PMID: 28818518.
230. Berg T, Simon KG, Mauss S, Schott E, Heyne R, Klass DM, Eisenbach C, Welzel TM, Zachoval R, Felten G, Schulze-Zur-Wiesch J, Cornberg M, Op den Brouw ML, Jump B, Reiser H, Gallo L, Warger T, Petersen J; FINITE CHB study investigators [First investigation in stopping TDF treatment after long-term virological suppression in HBeAg-negative chronic hepatitis B].:
Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
J Hepatol. 2017 Jul 21. pii: S0168-8278(17)32155-4. doi: 10.1016/j.jhep.2017.07.012. [Epub ahead of print] PMID: 28736139.
229. Janssen HLA, Chan HLY, Petersen J.:
Hepatitis B virus infection.
Best Pract Res Clin Gastroenterol. 2017 Jun;31(3):237. doi: 10.1016/j.bpg.2017.05.009. Epub 2017 Jun 9. No abstract available. PMID: 28774404.
228. Dandri M, Petersen J.:
Animal models of HBV infection.
Best Pract Res Clin Gastroenterol. 2017 Jun;31(3):273-279. doi: 10.1016/j.bpg.2017.04.014. Epub 2017 May 5. Review. PMID: 28774409.
227. Giersch K, Homs M, Volz T, Helbig M, Allweiss L, Lohse AW, Petersen J, Buti M, Pollicino T, Sureau C, Dandri M, Lütgehetmann M.:
Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized mice.
Sci Rep. 2017 Jun 16;7(1):3757. doi: 10.1038/s41598-017-03946-9. PMID: 28623307.
226. Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S; POLARIS-1 and POLARIS-4 Investigators.:
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512. PMID: 28564569.
225. Welzel TM, Hinrichsen H, Sarrazin C, Buggisch P, Baumgarten A, Christensen S, Berg T, Mauss S, Teuber G, Stein K, Deterding K, van Bömmel F, Heyne R, John C, Zimmermann T, Lutz T, Schott E, Hettinger J, Kleine H, König B, Hüppe D, Wedemeyer H.:
Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.
J Viral Hepat. 2017 Oct;24(10):840-849. doi: 10.1111/jvh.12708. Epub 2017 May 25. PMID: 28342229.
224. Allweiss L, Volz T, Giersch K, Kah J, Raffa G, Petersen J, Lohse AW, Beninati C, Pollicino T, Urban S, Lütgehetmann M, Dandri M.:
Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.
Gut. 2017 Apr 20. pii: gutjnl-2016-312162. doi: 10.1136/gutjnl-2016-312162. [Epub ahead of print] PMID: 28428345.
223. Kowdley KV, Sundaram V, Jeon CY, Qureshi K, Latt NL, Sahota A, Lott S, Curry MP, Tsai N, Chaiyakunapruk N, Lee Y, Petersen J, Buggisch P.:
Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.
Hepatology. 2017 Apr;65(4):1094-1103. doi: 10.1002/hep.29005. Epub 2017 Feb 25. Review. PMID: 28027579.
222. Bourgeois S, Van Vlierberghe H, Moreno C, Orlent H, Nevens F, Arastéh K, Horsmans Y, Schattenberg JM, Buggisch P, Francque S, Vijgen L, Kakuda TN, Hoeben E, Luo D, Vandebosch A, Jacquemyn B, Van Remoortere P, Verloes R.:
Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.
BMC Gastroenterol. 2017 Feb 10;17(1):26. doi: 10.1186/s12876-017-0580-2. PMID: 28187751.
221. Hézode C, Almasio PL, Bourgeois S, Buggisch P, Brown A, Diago M, Horsmans Y, Serfaty L, Szalay F, Gaeta GB, Planas R, Schlag M, Lonjon-Domanec I, Omoruyi E, DeMasi R, Zeuzem S.:
Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.
Liver Int. 2017 Sep;37(9):1304-1313. doi: 10.1111/liv.13376. Epub 2017 Mar 13. PMID: 28135777.
220. Cornberg M, Petersen J, Schober A, Mauss S, Böker KH, Link R, Günther R, Serfert Y, Pfeiffer-Vornkahl H, Manns MP, Sarrazin C, Hüppe D, Berg T, Niederau C.:
Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection.
Aliment Pharmacol Ther. 2017 Mar;45(5):688-700. doi: 10.1111/apt.13925. Epub 2017 Jan 12. PMID: 28078723.
219. Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Sanai F, Bicer C, Lenz O, Van Dooren G, Nalpas C, Lonjon-Domanec I, Schlag M, Buti M.:
Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response.
PLoS One. 2017 Jan 5;12(1):e0168713. doi: 10.1371/journal.pone.0168713. eCollection 2017. PMID: 28056030.
218. P. Buggisch, P. Atanasov, K. Wursthorn, A. Stoehr, J. Petersen:
SAT-254: Real-world effectiveness and cost per SVR of Sofosbuvir/ Velpatasvir chronic hepatitis C treatment
Journal of Hepatology, Volume 66, Issue 1, Supplement, 2017, Page s730
217. J. Petersen, K. Wursthorn, K. Olah, T. Lorenzen, A. Plettenberg, S. Unger, C. Czaja-Harder, A. Burchard, K. Matschenz, A. Stoehr, P. Buggisch:
FRI-252 - Strong decrease of patients with advanced liver disease and more adherence problems to HCV therapy as DAA regimen enter third year of existence in Germany
Journal of Hepatology, Volume 66, Issue 1, Supplement, 2017, Page s522 DOI: http://dx.doi.org/10.1016/S0168-8278(17)31446-0
216. Rockstroh JK, Ingiliz P, Petersen J, Peck-Radosavljevic M, Welzel TM, Van der Valk M, Zhao Y, Jimenez-Exposito MJ, Zeuzem S.:
Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
Antivir Ther. 2017;22(3):225-236. doi: 10.3851/IMP3108. Epub 2016 Nov 15. PMID: 27845298.
215. Marcellin P, Ahn SH, Chuang WL, Hui AJ, Tabak F, Mehta R, Petersen J, Lee CM, Ma X, Caruntu FA, Tak WY, Elkhashab M, Lin L, Wu G, Martins EB, Charuworn P, Yee LJ, Lim SG, Foster GR, Fung S, Morano L, Samuel D, Agarwal K, Idilman R, Strasser SI, Buti M, Gaeta GB, Papatheodoridis G, Flisiak R, Chan HL.:
Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.
Aliment Pharmacol Ther. 2016 Nov;44(9):957-966. doi: 10.1111/apt.13779. Epub 2016 Sep 15. PMID: 27629859.
214. Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, Berg T, Spengler U, Weiland O, van der Valk M, Rockstroh J, Peck-Radosavljevic M, Zhao Y, Jimenez-Exposito MJ, Zeuzem S.:
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
Gut. 2016 Nov;65(11):1861-1870. doi: 10.1136/gutjnl-2016-312444. Epub 2016 Sep 7. Erratum in: Gut. 2016 Dec;65(12 ):2060. PMID: 27605539.
213. Petersen J, Thompson AJ, Levrero M.:
Aiming for cure in HBV and HDV infection.
J Hepatol. 2016 Oct;65(4):835-48. doi: 10.1016/j.jhep.2016.05.043. Epub 2016 Jun 3. Review. PMID: 27270043.
212. Zoulim F, Białkowska-Warzecha J, Diculescu MM, Goldis AE, Heyne R, Mach T, Marcellin P, Petersen J, Simon K, Bendahmane S, Klauck I, Wasiak W, Janssen HL.:
Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure.
Hepatol Int. 2016 Sep;10(5):779-88. doi: 10.1007/s12072-016-9737-2. Epub 2016 May 20. PMID: 27206517.
211. Owens CM, Brasher BB, Polemeropoulos A, Rhodin MH, McAllister N, Peng X, Wang C, Ying L, Cao H, Lawitz E, Poordad F, Rondon J, Box TD, Zeuzem S, Buggisch P, Lin K, Qiu YL, Jiang L, Colvin R, Or YS.:
Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239.
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6207-15. doi: 10.1128/AAC.00808-16. Print 2016 Oct. PMID: 27503640.
210. Hüppe D, Buggisch P, Christensen S, Heiken H, Mauss S, Naumann U, Fischer C, Kleine H, Huelsenbeck J.:
Chronic hepatitis C patients prior to broad access to interferon-free treatments in Germany.
Z Gastroenterol. 2016 Aug;54(8):740-7. doi: 10.1055/s-0042-106731. Epub 2016 Aug 16. PMID: 27529525.
209. Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Ryan R, Lenz O, Scott J, Van Dooren G, Lonjon-Domanec I, Schlag M, Buti M.:
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).
PLoS One. 2016 Jul 18;11(7):e0158526. doi: 10.1371/journal.pone.0158526. eCollection 2016. PubMed PMID: 27428331.
208. Tacke F, Günther R, Buggisch P, Klinker H, Schober A, John C, Lutz T, Pfeiffer-Vornkahl H, Niederau C, Cornberg M, Sarrazin C, Mauss S.:
Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower SVR rates in real life than expected from clinical trials.
Liver Int. 2016 Jul 18. doi: 10.1111/liv.13206. [Epub ahead of print] PubMed PMID: 27428297.
207 Fülöp B, Mihm U, Rohde P, Buggisch P, Schlosser B, Biermer M, Brodzinski A, Fischer J, Böhm S, van Bömmel F, Sarrazin C, Berg T.:
Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type.
J Viral Hepat. 2016 Jun 26. doi: 10.1111/jvh.12562. [Epub ahead of print] PubMed PMID: 27346846.
206. Fischer J, Weber AN, Böhm S, Dickhöfer S, El Maadidi S, Deichsel D, Knop V, Klinker H, Möller B, Rasenack J, Wang L, Sharma M, Hinrichsen H, Spengler U, Buggisch P, Sarrazin C, Pawlita M, Waterboer T, Wiese M, Probst-Müller E, Malinverni R, Bochud PY, Gardiner CM, O'Farrelly C, Berg T.:
Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection.
Gut. 2016 Apr 21. pii: gutjnl-2015-310239. doi: 10.1136/gutjnl-2015-310239. [Epub ahead of print] PubMed PMID: 27196570.
205. Maura Dandri, Joerg Petersen:
Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.
CID 2016:62 (Suppl 4) S281.
204. George Papatheodoridis, Ioannis Vlachogiannakos, Evangelos Cholongitas, Karsten Wursthorn, Christos Thomadakis, Giota Touloumi, Jörg Petersen:
Discontinuation of Oral Antivirals in Chronic Hepatitis B: A Systematic Review.
HEPATOLOGY, VOL. 63, NO. 5, 2016.
203. Murray JM, Stancevic O, Lütgehetmann M, Wursthorn K, Petersen J, Dandri M.
J Theor Biol. 2016 Feb 21;391:74-80. doi: 10.1016/j.jtbi.2015.12.005. Epub 2015 Dec 23. PMID: 26723531.
202. P. Buggisch, K. Wursthorn, A. Stoehr, A. Gauthier, J. Petersen:
SAT-240: Real-World Effectiveness and Cost per Sustained Viral Response of Ledipasvir/Sofosbuvir Chronic Hepatitis C Treatment
Journal of Hepatology, Volume 64, Issue 2, Supplement, 2016, Pages s809-s810
201. P. Buggisch, K. Wursthorn, A. Stoehr, A. Gauthier, J. Petersen:
SAT-243: Real-World Effectiveness of Ledipasvir/Sofosbuvir 8 Weeks Chronic Hepatitis C Treatment
Journal of Hepatology, Volume 64, Issue 2, Supplement, 2016, Page s811
200. J.Petersen, K.Wursthorn, K.Olah, T.Lorenzen, A.Plettenberg, S.Unger, C.Czaja-Harder, K.Matschenz, A.Stoehr, P.Buggisch_
SAT-185: Failure with DAA Regimens in a High Volume Treatment Center under Real Life Conditions
Journal of Hepatology, Volume 64, Issue 2, Supplement, 2016, Page s782
199. Christian Hoffmann, Philipp Schommers, Eva Wolf, Markus Muller, Alexander Schultze , Ivanka Krznaric, Albrecht Stoehr , Timo Wolf , Gerd Faetkenheuer , Bastian Stier , Christoph Wyen, Marcus Hentrich:
CD4R and CD8R T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphoma
Christian Hoffmann, Philipp Schommers, Eva Wolf, Markus Muller, Alexander Schultze , Ivanka Krznaric, Albrecht Stoehr , Timo Wolf , Gerd Faetkenheuer , Bastian Stier , Christoph Wyen, Marcus Hentrich
198. Eugénio Teófilo, Nuno Rocha-Pereira, Birger Kuhlmann, Antonio Antela, Heribert Knechten, Jesús Santos, Maria Jesús Jiménez-Expósito, on behalf of the REMAIN study group (including A. Stoehr):
Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study
HIV Clin Trials. 2016 Jan 2; 17(1): 17–28. Published online 2016 Feb 5. doi: 10.1080/15284336.2015.1112494
197. Cooper DA, Cordery DV, Zajdenverg R, Ruxrungtham K, Arastéh K, Bergmann F, Neto JL, Scherer J, Chaves RL, Robinson P; study team (including A. Stoehr):
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
PLoS One. 2016 Jan 5;11(1):e0144917. doi: 10.1371/journal.pone.0144917. eCollection 2016.
196. Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F; NEAT 001/ANRS 143 Study Group.:
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
J Antimicrob Chemother. 2016 Apr;71(4):1056-62. doi: 10.1093/jac/dkv427. Epub 2015 Dec 24. PMID: 26702926
195. Friedrich-Rust M, Lupsor M, de Knegt R, Dries V, Buggisch P, Gebel M, Maier B, Herrmann E, Sagir A, Zachoval R, Shi Y, Schneider MD, Badea R, Rifai K, Poynard T, Zeuzem S, Sarrazin C:
Point Shear Wave Elastography by Acoustic Radiation Force Impulse Quantification in Comparison to Transient Elastography for the Noninvasive Assessment of Liver Fibrosis in Chronic Hepatitis C: A Prospective International Multicenter Study.
Ultraschall Med. 2015 May 13. [Epub ahead of print] PubMed PMID: 25970201.
194. Schmidt D, Kollan C, Stoll M, Stellbrink HJ, Plettenberg A, Fätkenheuer G, Bergmann F, Bogner JR, van Lunzen J, Rockstroh J, Esser S, Jensen BE, Horst HA, Fritzsche C, Kühne A, an der Heiden M, Hamouda O, Bartmeyer B; ClinSurv Study Group.:
From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany.
BMC Public Health. 2015 Mar 17;15:252. doi: 10.1186/s12889-015-1598-4. PMID: 25848706
193. Sarrazin C, Berg T, Buggisch P, Dollinger MM, Hinrichsen H, Hofer H, Hüppe D, Manns MP, Mauss S, Petersen J, Simon KG, van Thiel I, Wedemeyer H, Zeuzem S:
[S3 guideline hepatitis C addendum]. Z Gastroenterol. 2015 Apr;53(4):320-34. doi: 10.1055/s-0034-1399322. Epub 2015 Apr 13. German. PubMed PMID: 25867048.
192. Fülöp B, Biermer M, Cornberg M, Wedemeyer H, Port K, Heyne R, Zeuzem S, Peiffer KH, Welzel T, Herber A, Buggisch P, Moser C, Stoll S, Alshuth U, Berg T:
Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders.
Liver Int. 2015 Mar 19. doi: 10.1111/liv.12832. [Epub ahead of print] PubMed PMID: 25801095.
191. Daniel Schmidt, Christian Kollan, Matthias Stoll, Hans-Jürgen Stellbrink, Andreas Plettenberg,
Gerd Fätkenheuer, Frank Bergmann, Johannes R Bogner, Jan van Lunzen, Jürgen Rockstroh, Stefan Esser,
Björn-Erik Ole Jensen, Heinz-August Horst, Carlos Fritzsche, Andrea Kühne, Matthias an der Heiden,
Osamah Hamouda, Barbara Bartmeyer and ClinSurv Study Group:
From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany
BMC Public Health (2015) 15:252 DOI 10.1186/s12889-015-1598-4
190. Jorg Petersen, Maura Dandri:
Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy?
Liver International 2015; 35 (Suppl. 1): 114–120
189. Maribel Rodriguez–Torres, Albrecht Stoehr, Edward J. Gane, Lawrence Serfaty, Eric Lawitz, Amy Zhou, Michael Bourque, Sanhita Bhanja, Julie Strizki, Richard J. O. Barnard, Peggy M. T. Hwang, Mark J. DiNubile, Niloufar Mobashery:
Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis.
Clinical Gastroenterology and Hepatology 2014; 12:1029–1037
188. Sarrazin C, Berg T, Buggisch P, Dollinger M, Hinrichsen H, Hüppe D, Manns M, Mauss S, Petersen J, Simon KG, van Thiel I, Wedemeyer H, Zeuzem S:
Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C.
Z Gastroenterol. 2014 Oct;52(10):1185-97. German. PubMed PMID: 25513400.
187. Heidrich B, Wiegand SB, Buggisch P, Hinrichsen H, Link R, Möller B, Böker KH, Teuber G, Klinker H, Zehnter E, Naumann U, Busch HW, Maasoumy B, Baum U, Hardtke S, Manns MP, Wedemeyer H, Petersen J, Cornberg M; HepNet Study Group:
Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA.
PLoS One. 2014 Oct 10;9(10):e108751. doi: 10.1371/journal.pone.0108751. eCollection 2014. PubMed PMID: 25302676; PubMed Central PMCID: PMC4193764.
186. Wiegand J, Maasoumy B, Buggisch P, Buslau A, Schiefke I, Berg T, Wedemeyer H, Sarrazin C, Hinrichsen H. Letter:
Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis.
Aliment Pharmacol Ther. 2014 Jun;39(11):1342-4. doi: 10.1111/apt.12748. PubMed PMID: 24803258.
185. Thomas Harrer, Andreas Plettenberg, Keikawus Arastéh, Jan Van Lunzen, Gerd Fätkenheuer, Hans Jaeger, Michel Janssens, Wivine Burny, Alix Collard, François Roman, Alfred Loeliger, Marguerite Koutsoukos, Patricia Bourguignon, Ludo Lavreys, Gerald Voss:
Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: A randomised placebo-controlled study.
Vaccine, Volume 32, Issue 22, 7 May 2014, Pages 2657-2665
184. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; ION-1 Investigators:
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
N Engl J Med. 2014 May 15;370(20):1889-98. doi: 10.1056/NEJMoa1402454. Epub 2014 Apr 11. PubMed PMID: 24725239.
183. Allweiss L, Volz T, Lütgehetmann M, Giersch K, Bornscheuer T, Lohse AW, Petersen J, Ma H, Klumpp K, Fletcher SP, Dandri M:
Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration.
J Hepatol. 2014 Mar; 60(3):500-7
182. Giersch K, Helbig M, Volz T, Allweiss L, Mancke LV, Lohse AW, Polywka S, Pollok JM, Petersen J, Taylor J, Dandri M, Lütgehetmann M:
Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection.
J Hepatol. 2014 Mar; 60(3):538-44
181. Grammatikos G, Lange C, Susser S, Schwendy S, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Penna-Martinez M, Badenhoop K, Zeuzem S, Berg T, Sarrazin C:
Vitamin D Levels Vary during Antiviral Treatment but Are Unable to Predict Treatment Outcome in HCV Genotype 1 Infected Patients.
PLOS ONE, 07 Feb 2014 ; 9(2):e87974
180. Marcellin P, Cooper C, Balart L, Larrey D,Box T, Yoshida E, Lawitz E, Buggisch P, Ferenci P, Weltman M, Labriola–Tompkins E, Le Pogam S, Nájera I, Thomas D, Hooper G, Shulman NS, Zhang Y, Navarro MT, Lim CY, Brunda M, Terrault NA, Yetzer ES:
Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection.
Gastroenterology 2013 Oct. Vol. 145, Issue 4, Pages 790-800.e3
179. Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, Martins EB, Yee LJ, Flaherty JF, Kitrinos KM, Rustgi VK, Marcellin P:
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
Hepatology. 2013 Aug; 58(2):505-13
178. Klaus Jansen, Burkhard Haastert, Claudia Michalik, Adrienne Guignard, Stefan Esser, Stephan Dupke, Andreas Plettenberg, Adriane Skaletz-Rorowski, Norbert H Brockmeyer:
Incidence and risk factors of herpes zoster among hiv-positive patients in the german competence network for HIV/AIDS (KompNet): a cohort study analysis
BMC Infectious Diseases 2013, 13:372
177. Deterding K, Grüner N, Buggisch P, Wiegand J, Galle PR, Spengler U, Hinrichsen H, Berg T, Potthoff A, Malek N, Großhennig A, Koch A, Diepolder H, Lüth S, Feyerabend S, Jung MC, Rogalska-Taranta M, Schlaphoff V, Cornberg M, Manns MP, Wedemeyer H;:
Hep-Net Acute HCV-III Study Group. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial.
Lancet Infect Dis. 2013 Jun; 13(6):497-506
176. Zoutendijk R, Reijnders JG, Brown A, Zoulim F, Mutimer D, Deterding K, Petersen J, Peter Hofmann W, Buti M, Santantonio T, van Bömmel F, Pradat P, Oo Y, Luetgehetmann M, Berg T, Hansen BE, Wedemeyer H, Janssen HL; for the VIRGIL Surveillance Study Group:
Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response.
Hepatology. 2011 Aug;54(2):443-451
175. Zoutendijk R, Reijnders JG, Zoulim F, Brown A, Mutimer DJ, Deterding K, Hofmann WP, Petersen J, Fasano M, Buti M, Berg T, Hansen BE, Sonneveld MJ, Wedemeyer H, Janssen HL; VIRGIL Surveillance Study Group:
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis.
Gut. 2013 May; 62(5):760-5
174. Volz T, Allweiss L, Ben MBarek M, Warlich M, Lohse AW, Pollok JM, Alexandrov A, Urban S, Petersen J, Lütgehetmann M, Dandri M:
The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.
J Hepatol. 2013 May; 58(5):861-7
173. Friedrich-Rust M, Buggisch P, de Knegt RJ, Dries V, Shi Y, Matschenz K, Schneider MD, Herrmann E, Petersen J, Schulze F, Zeuzem S, Sarrazin C:
Acoustic radiation force impulse imaging for non-invasive assessment of liver fibrosis in chronic hepatitis B.
J Viral Hepat. 2013 Apr; 20(4):240-7
172. Burger D, Back D, Buggisch P, Buti M, Craxí A, Foster G, Klinker H, Larrey D, Nikitin I, Pol S, Puoti M, Romero-Gómez M, Wedemeyer H, Zeuzem S::
Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions.
J Hepatol. 2013 Apr; 58(4):792-800
171. Knop V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Neumann K, Sarrazin C, Zeuzem S, Berg T::
Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy.
Ann Hepatol. 2013 Mar-Apr; 12(2):190-8
170. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C, Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, Chen Y, Porta C:
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
Lancet Oncol. 2013 Jan; 14(1):55-63
169. Dandri M, Lütgehetmann M, Petersen J:
Experimental models and therapeutic approaches for HBV.
Semin Immunopathol. 2013 Jan; 35(1):7-21
168. Petersen J, Buti M:
Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs.
Expert Rev Gastroenterol Hepatol. 2012 Dec; 6(6):683-93
167. Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Heinze L, Spengler U, Schlaepfer T, Reimer J, Buggisch P, Ockenga J, Link R, Rentrop M, Weidenbach H, Fromm G, Lieb K, Baumert TF, Heinz A, Discher T, Neumann K, Zeuzem S, Berg T:
Escitalopram for the Prevention of Peginterferon-a2a-Associated Depression in Hepatits C Virus-Infected Patients Without Previous Psychiatric Disease: A Randomized Trial.
Ann Intern Med. 2012 Jul 17; 157(2):94-103
166. Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, Mo H, Arterburn S, Knox S, Oldach D, McHutchison JG, Manns MP, Foster GR:
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
Hepatology. 2012 Mar; 55(3):749-58
165. Petersen J, Ratziu V, Buti M, Janssen HL, Brown A, Lampertico P, Schollmeyer J, Zoulim F.Wedemeyer H, Sterneck M, Berg T, Sarrazin C, Lutgehetmann M, Buggisch P:
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis b patients: an international multicenter cohort study.
J Hepatol. 2012 Mar; 56(3):520-6
164. Lütgehetmann M, Mancke LV, Volz T, Helbig M, Allweiss L, Bornscheuer T, Pollok JM, Lohse AW, Petersen J, Urban S, Dandri M:
Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.
Hepatology. 2012 Mar; 55(3):685-94
163. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, Levrero M:
IFN-a inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome.
J Clin Invest. 2012 Feb 1; 122(2):529-37
162. Cacoub P, Bourlière M, Lübbe J, Dupin N, Buggisch P, Dusheiko G, Hézode C, Picard O, Pujol R, Segaert S, Thio B, Roujeau JC:
Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals.
J Hepatol. 2012 Feb; 56(2)
161. Volz T, Lütgehetmann M, Allweiss L, Warlich M, Bierwolf J, Pollok JM, Petersen J, Matthes E, Dandri M:
Strong antiviral activity of the new l-hydroxycytidine derivative, l-Hyd4FC, in HBV-infected human chimeric uPA/SCID mice.
Antivir Ther. 2012; 17(4):623-31
160. Wiegand J, Neumann K, Böhm S, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Sarrazin C, Berg T:
Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection.
Clin Infect Dis. 2011 Dec; 53(11):1111-4
159. Weich V, Herrmann E, Chung TL, Sarrazin C, Hinrichsen H, Buggisch P, Gerlach T, Klinker H, Spengler U, Bergk A, Zeuzem S, Berg T:
The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection.
J Gastroenterol. 2011 Dec; 46(12):1427-36
158. Petersen J:
HBV treatment and pregnancy.
J Hepatol. 2011 Dec; 55(6):1171-3
157. Sarrazin C, Schwendy S, Möller B, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Prinzing R, Herrmann E, Zeuzem S, Berg T:
Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.
Gastroenterology. 2011 Nov; 141(5):1656-64
156. Petersen J:
[Hepatitis B in clinical practice].
Med Monatsschr Pharm. 2011 Nov; 34(11):402-14
155. Benten D, Schulze Zur Wiesch J, Sydow K, Koops A, Buggisch P, Böger RH, Gaydos CA, Won H, Franco V, Lohse AW, Ray SC, Balagopal A:
The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS).
BMC Gastroenterol. 2011 Oct 6; 11:107
154. Grabowski J, Yurdaydìn C, Zachou K, Buggisch P, Hofmann WP, Jaroszewicz J, Schlaphoff V, Manns MP, Cornberg M, Wedemeyer H; HIDIT-1 study group:
Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
Liver Int. 2011 Oct; 31(9):1395-405
153. Manns M, Zeuzem S, Sood A, Lurie Y, Cornberg M, Klinker H, Buggisch P, Rossle M, Hinrichsen H, Merican I, Ilan Y, Mauss S, Abu-Mouch S, Horban A, Muller TH, Welsch C, Chen R, Faruqi R, Pedicone LD, Wedemeyer H:
Reduced Dose and Duration of Peginterferon alfa-2b and Weight-Based Ribavirin in Patients With Genotype 2 and 3 Chronic Hepatitis C.
152. Dandri M, Petersen J:
Chimeric Mouse Model of Hepatitis B Virus infection.
J Hepatol. 2011 Jul 26
151. Cornberg M, Protzer U, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S, Sarrazin C, Dollinger MM, Schirmacher P, Dathe K, Kopp IB, Zeuzem S, Gerlich WH, Manns MP; AWMF:
[Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline].
Z Gastroenterol. 2011 Jul; 49(7):871-930
150. Lütgehetmann M, Bornscheuer T, Volz T, Allweiss L, Bockmann JH, Pollok JM, Lohse AW, Petersen J, Dandri M:
Hepatitis B virus limits response of human hepatocytes to interferon-a in chimeric mice.
Gastroenterology. 2011 Jun; 140(7):2074-83
149. Schulze Zur Wiesch J, Pudelski N, Hoepner L, Supplieth M, Buggisch P, Lohse AW, Lüth S:
"Real-Life" comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus.
Hepatology. 2011 Apr.; 53(4):1405-6; author reply 1407
148. Cornberg M, Protzer U, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth A, Sarrazin C, Dollinger MM, Schirmacher P, Dathe K, Kopp IB, Zeuzem S, Gerlich WH, Manns MP:
Aktualisierung der S3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion.
Z Gastroenterol 2011; 49: 871-930
147. Plettenberg A, Brockmeyer NH, Haastert B, Michalik C, Dupke S, Schewe K, Rausch M, Hower M, Ulmer A, Wolf E, Lorenzen T, Arendt G, Jansen K; the Competence Network for HIV/AIDS:
Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS.
Infection 2011; 38 (1)
146. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F:
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Gastroenterology 2011; 140:132-43
145. Duprez DA, Neuhaus J, Tracy R, Kuller LH, Deeks SG, Orkin C, Stoehr A, Woolley IJ, Neaton JD; for the INSIGHT SMART Group:
N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients.
AIDS 2011; 15
144. Lutgehetmann M, Meyer F, Volz T, Lohse AW, Fischer C, Dandri M, Petersen J:
Knowledge about HBV, prevention behaviour and treatment adherence of patients with chronic hepatitis B in a large referral centre in Germany.
Z Gastroenterol. 2010 Sep.; 48(9):1126-32
143. Lutgehetmann M, Volz T, Köpke A, Broja T, Tigges E, Lohse AW, Fuchs E, Murray JM, Petersen J, Dandri M:
In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice.
Hepatology. 2010 Jul.; 52(1):16-24
142. Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, van Bömmel F, Hansen BE, Wedemeyer H, Janssen HL; VIRGIL Surveillance Study Group:
Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
J Hepatol. 2010 Apr.; 52(4):493-500. Epub 2010 Feb 4
141. Urban S, Schulze A, Dandri M, Petersen J:
The replication cycle of hepatitis B virus.
J Hepatol. 2010 Feb.; 52(2):282-4. Epub 2009 Nov 24
140. Gehling UM, Willems M, Schlagner K, Benndorf RA, Dandri M, Petersen J, Sterneck M, Pollok JM, Hossfeld DK, Rogiers X:
Mobilization of hematopoietic progenitor cells in patients with liver cirrhosis.
World J Gastroenterol. 2010 Jan.; 16(2):217-24
139. van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Hüppe D, Stein K, Trojan J, Sarrazin C, Böcher WO, Spengler U, Wasmuth HE, Reinders JG, Möller B, Rhode P, Feucht HH, Wiedenmann B, Berg T:
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.
Hepatology. 2010 Jan.; 51(1):73-80
138. Moyle G, Boffito M, Stoehr A, Rieger A, Shen Z, Manhard K, Sheedy B, Hingorani V, Raney A, Nguyen M, Nguyen T, Ong V, Yeh LT, Quart B:
Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects.
Antimicrob Agents Chemotherapy 2010; 54(8):3170-8
137. Vogel M, Ahlenstiel G, Hintsche B, Fenske S, Trein A, Lutz T, Schurmann D, Stephan C, Khaykin P, Bickel M, Mayr C, Baumgarten A, Buggisch P, Klinker H, John C, Golz J, Staszewski S, Rockstroh JK:
The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals.
Eur J Med Res 2010; 15:102-11
136. Knechten H, Stephan C, Mosthaf FA, Jaeger H, Lutz T, Cargnico A, Stoehr A, Koeppe S, Mayr C, Schewe K, Wolf E, Wellmann E, Tappe A:
Safety and efficacy of a saquinavir-containing antiretroviral regimen in previously ART-naïve or pretreated but protease inhibitor-naïve HIV-positive patients.
Infection. 2010; 38 (2):108-16
135. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M:
Control of cccDNA function in hepatitis B virus infection.
J Hepatol. 2009 Sep.; 51(3):581-92
134. Pulido F, Estrada V, Baril JG, Logue K, Schewe K, Plettenberg A, Duiculescu D, Yau L, Vavro C, Lim ML, Pharo C:
Long-Term Efficacy and Safety of Fosamprenavir plus Ritonavir Versus Lopinavir/Ritonavir in Combination with Abacavir/lamivudine over 144 Weeks.
HIV Clin Trials 2009; 10(2):76-78
133. Berg T, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Pape GR, Spengler U, Buggisch P, Balk H, Zankel M, Neumann K, Sarrazin C, Zeuzem S:
Individualized Treatment Strategy with Peginterferon Alfa-2b (Peg-IFN a-2b) Plus Ribavirin According to Early Viral Kinetics in Hepatitis C Virus (HCV) Type 1-Infected Patients.
Hepatology 2009; 50 :269-377
132. Lorenzen T, Walther I, Stoehr A, Salzberger A, Plettenberg A of the Radata Study Group:
Effective Trearment of Patientsin an Deep Salvage Situation with Non-Active HAART: Experiences with the Expert Advice System Radata.
Infection 2009; 37 (6): 528-533
131. Deterding K, Wiegand J, Gruner N, Hahn A, Jackel E, Jung MC, Buggisch P, Galle; Berg T, Hinrichsen H, Potthoff A, Zeuzem S, Cornberg M, Manns M, Wedemeyer H:
The German Hep-Net Acute Hepatitis C Cohort: Impact of Viral and Host Factors on the Initial Presentation of Acute Hepatitis C Virus Infection.
Z Gastroenterol 2009; 47: 531-540
130. Schulze Zur Wiesch J, Pieper D, Stahmer I, Eiermann T, Buggisch P, Lohse A, Hauber J, van Lunzen J:
Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection.
Clin Infect Dis 2009; 49: 466-472
129. Fätkenheuer G, Staszewski S, Plettenberg A, Hackman F, Layton G, McFadyen L, Davis J, Jenkins TM:
Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients.
AIDS. 2009; 23(16):2115-22
128. Jansen K, Michalik C, Hahn M, Dupke S, Esser S, Jäger H, Köppe S, Moll A, Plettenberg A, Schmidt RE, Skaletz-Rorowski A, Brockmeyer NH and the Competence Network for HIV/AIDS:
The Patient Cohort of the German Competence Network for HIV/ AIDS (KompNet): A Profile.
Eur J Med Res 2009; 8: 323 - 331
127. Kremer H, Sonnenberg-Schwan U, Arendt G, Brockmeyer N H, Potthoff A, Ulmer A, Graefe K, Lorenzen T, Starke W, Walker U A fort he German Competence Network HIV/AIDS:
HIV or HIV-Therapy? Causal Attributions Of Symptoms And Their Impact On Treatment Decisions Among Women And Men With HIV.
EUT J Med Res 2009; 14:139-146
126. von Wagner M, Hofmann WP, Teuber G, Berg T, Goeser T, Spengler U, Hinrichsen H, Weidenbach H, Gerken G, Manns M, Buggisch P, Herrmann E, Zeuzem S:
Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.
Hepatology. 2008 Nov.; 48(5):1404-11
125. Dandri M, Murray JM, Lutgehetmann M, Volz T, Lohse AW, Petersen J:
Virion half-life in chronic hepatitis B infection is strongly correlated with levels of viremia.
Hepatology. 2008 Oct; 48(4):1079-86
124. Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S, Schirmacher P, Fleig WE, Manns MP; German Society for Digestive and Metabolic Diseases; German Society for Pathology; Society for Virology; Society for Pediatric Gastroenterology and Nutrition; Competence Network for Viral Hepatitis:
The German guideline for the management of hepatitis B virus infection: short version.
J Viral Hepat. 2008 Aug; 15 Suppl 1:1-21
123. Petersen J, Dandri M, Mier W, Lütgehetmann M, Volz T, von Weizsäcker F, Haberkorn U, Fischer L, Pollok JM, Erbes B, Seitz S, Urban S:
Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.
Nat Biotechnol. 2008 Mar.; 26(3):335-41. Epub 2008 Feb 24
122. Marcellin P, Buti M, Krastev Z, Germanidis G., Kaita K., Kotzev I, Buggisch P, Weilert F, Trinh H, Sorbel J, Anderson J., Mondou E, Quinn J, Rousseau F:
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B.
NEJM 2008; 359: 2442-55
121. Halangk J, Sarrazin C, Neumann K, Puhl G, Mueller T, Teuber G, Klinker H, Hinrichsen H, Buggisch P, Landt O, Weich V, Bergk A, Wiedenmann B, Neuhaus P, Berg T, Witt H:
Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection.
J Hepatol 2008; 49:339-45
120. Reinel D, Plettenberg A, Seebacher C, Abeck D, Brasch J, Cornely O, Effendy I, Ginter-Hanselmeyer G, Haake N, Hamm G, Hipler U-C, Hof H, Korting H C, Mayser P, Ruhnke M, Schlacke K-H, Tietz H-J:
Leitlinie Orale Candidose.
JDDG 2008; 7: 593 - 597
119. Hennes EM, Oo YH, Schramm C, Denzer U, Buggisch P, Wiegard C, Kanzler S, Schuchmann M, Boecher W, Galle PR, Adams DH, Lohse AW:
Mycophenolate Mofetil as Second Line Therapy in Autoimmune Hepatitis?.
Am J Gastroenterol 2008; 103:1-8
118. Rodriguez-Torres M, Govindarajan S, Sola R, Clumeck N, Lissen E, Pessoa M, Buggisch P, Main J, Depamphilis J, Dieterich DT:
Hepatic steatosis in HIV/HCV co-infected patients: Correlates, efficacy and outcomes of anti-HCV therapy: A paired liver biopsy study.
J Hepatol 2008; 48:756-64
117. Stoehr A, Brinkmann K, Sabranski M:
Diese Leber braucht dringend eine Therapie.
MMW 2008; Sonderheft 1:54 - 57
116. Lutgehetmann M, Volzt T, Quaas A, Zankel M, Fischer C, Dandri M, Petersen J:
Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.
Antivir Ther. 2008; 13(1):57-66
115. Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S, Schirmacher P, Fleig WE, Manns MP:
Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection.
Z Gastroenterol. 2007 Dec; 45(12):1281-328
114. Volz T, Lutgehetmann M, Wachtler P, Jacob A, Quaas A, Murray JM, Dandri M, Petersen J:
Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients.
Gastroenterology. 2007 Sep; 133(3):843-52
113. Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S, Schirmacher P, Fleig WE, Manns MP:
[Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011].
Z Gastroenterol. 2007 Jun; 45(6):525-74
112. Steffen M, Cornberg M, Buggisch P:
Treatment of chronic hepatitis C with consensus interferon in relapsers and non-responders to interferon-based therapy.
Hepatogastroenterology. 2007; 54(80):2368-72
111. Salzberger B, Däumer M, Gute P, Jäger H, Knechten H, van Lunzen J, Mauss S, Mayr C, Moll A, Plettenberg A, Rockstroh J, Staszewski S, Stellbribk HJ, Stoll M, Stuermer M:
Enfuvirtid bei mehrfach vorbehandelten HIV-Patienten. Konsensus-Empfehlung einer deutschen Expertengruppe.
AMT 2007; 12 (25): 454 - 461
110. Lorenzen T, Stoehr A, Walther I, Plettenberg A:
CCR5 Antagonists in the treatment of treatment-experienced patients infectes with CCR5 tropic HIV-1.
Eur J Med Res 2007; 12: 419 - 425
109. Schachler E, Brockmeyer N, Effendy I, Geiss HK, Harder S, Hartmann M, Jappe U, Plettenberg A, Rasokat H, Reismann H, Shah P, Stücker M, Wichelhaus TA, Schöfer H:
Streptokokkeninfektionen der Haut und Schleimhäute.
JDDG 2007; 6: 527-532
108. Salzberger B, Däumer M, Gute P, Jäger H, Knechten H, van Lunzen J, Mauss S, Mayr C, Moll A, Plettenberg A, Rockstroh J, Staszewski S, Stellbrink HJ, Stoll M, Stürmer M:
Consensus recommendation from a group of German experts for the use of Enfurvitide in heavily pretreated HIV patients.
Eur J Med Res 2007; 12:93-102
107. Hoffmann C, Wolf E, Wyen C, Fätkenheuer G, van Lunzen J, Stellbrink H-J, Stoehr A, Plettenberg A, Jäger H, Noppeney R, Hentrich M, Goekbuget N, Hölzer D, Horst H-A:
AIDS-associated Burkitt or Burkitt-like lymphoma: Short intensive polychemotherapy is feasible and effective.
Leukemia & Lymphoma 2006 Sep.; 47(9): 1872 - 1880
106. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J:
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.
Hepatology. 2006 Sep; 44(3):675-84
105. Török E, Vogel C, Lütgehetmann M, Ma PX, Dandri M, Petersen J, Burda MR, Siebert K, Düllmann J, Rogiers X, Pollok JM:
Morphological and functional analysis of rat hepatocyte spheroids generated on poly(L-lactic acid) polymer in a pulsatile flow bioreactor.
Tissue Eng. 2006 Jul; 12(7):1881-90
104. Dandri M, Lutgehetmann M, Volz T, Petersen J:
Small animal model systems for studying hepatitis B virus replication and pathogenesis.
Semin Liver Dis. 2006 May; 26(2):181-91
103. Lamarca A, Clumeck N, Plettenberg A, Domingo P, Fu K, Craig C, Zhao H, Watson M, Gordon D, Scott T:
Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study).
J Acquir Immune Defic Syndr. 2006 Apr.; 41(5):598-606
102. Rathmann W, Kammal M, Schröder S, Stoehr A, Schulz F:
Chronisch fibrosierende (sklerosierende) Peritonitis als Ursache des "plötzlichen" Todes.
Rechtsmedizin 2006; 16 (2): 69-72
101. Stocker H, Kloft C, Plock N, Breske A, Kruse G, Herzmann C, Schulbin, Kreckel P, Weber C, Goebel F, Roeling J, Staszewski S, Plettenberg A, Moecklinghoff C, Arastéh K, Kurowski M:
Pharmacokinetics of Enfuvirtide in Patients Treated in Typical Routine Clinical Settings.
Antimicrob Agents Chemother 2006; 50(2): 667-673
100. Wursthorn K, Buggisch P, Lutgehetmann M, Zollner B, Petersen J:
Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV.
Antivir Ther. 2006; 11(5):647-52